SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) June 5, 2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that the
second module of its modular premarket approval
application (PMA) submission for the Diasensor 2000 was
submitted to the FDA. This module includes the results
of testing conducted to verify that the Diasensor meets
electrical and mechanical standards for safety and
effectiveness as required by the FDA. Also contained
in Module Two is a summary of previous clinical study
results along with a description of how the Company's
glucose monitor will be used by patients.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: June 5, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL SUBMITS SECOND MODULE FOR DIASENSOR 2000 TO FDA
Pittsburgh, PA (June 5, 2000) - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that the second module of its
modular premarket approval application (PMA) submission for the
Diasensor 2000 was submitted to the FDA. This module includes
the results of testing conducted to verify that the Diasensor
meets electrical and mechanical standards for safety and
effectiveness as required by the FDA. Also contained in Module
Two is a summary of previous clinical study results along with a
description of how the Company's glucose monitor will be used by
patients.
Module One of the Company's PMA submission, which contained
a description of Biocontrol's manufacturing methods, facilities
and controls, including design controls as required by FDA
regulations, was previously submitted.
The Diasensor 2000 model is similar to the Diasensor 1000
but has software and hardware enhancements to provide for its use
within a telemedicine healthcare management program for people
with diabetes.
The Company has its corporate offices in Pittsburgh, PA and
is involved in the development and manufacture of biomedical
devices and environmental products. The company's subsidiaries
include Diasensor.com, ViaCirQ, Inc. and Petrol Rem, Inc. All
are located in Pittsburgh, PA.
WEB SITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204
This press release contains statements of a forward-looking
nature. Shareholders and potential investors are cautioned
that such statements are predictions and actual events or results
may vary significantly.
###
